Clareo Health | A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
40–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of COPD with symptoms for more than one year before screening
Body mass index of 18-30 kg/m2 and weight of 50-100kg
Current or ex-smokers with a smoking history of at least 10 pack years (1 pack year = tobacco consumption corresponding to 20 cigarettes smoked per day for one year) at screening
FEV1 of 30% or above and less than 80% of the predicted normal value post-bronchodilator at screening
FEV1/FVC less than 70% post-bronchodilator at screening
You may not be if
Any clinically significant disease or disorder
Exacerbation of COPD which was not resolved within 30 days of first dosing
Patients who have received live or live-attenuated vaccine in the 2 weeks prior to first dosing
Asthma and any current respiratory tract disorder other than COPD which is considered to be clinically significant
Disease history suggesting reduced or abnormal immune function other than that related to COPD
